Crestor on track for action in mid-2002
Executive Summary
AstraZeneca submits NDA for Crestor (rosuvastatin) to FDA June 26. The company expects a standard review for the cholesterol-lowering agent. A decision on whether to sign up a co-promotion partner is expected shortly (1"The Pink Sheet" June 18, p. 10)
You may also be interested in...
AstraZeneca Crestor Copromotion Decision Coming: Nexium Has 6% Share
AstraZeneca expects to make a decision on whether to use a copromotion partner for the HMG-CoA reductase inhibitor Crestor (rosuvastatin) within "the next six to eight weeks," CFO Jonathan Symonds told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials